COVID-19 VACCINATION DECISION TREE

**Pfizer-BioNTech Vaccine**
- >12 years old: 0.3mL x 2 doses 3-8 weeks apart
- 5-11 years old: 0.2mL x 2 doses 21 days apart

**Moderate to severely Immunocompromised**
- 3rd Additional Dose
  - Moderna >18 year old
  - Pfizer ≥ 5 years old
  - ≥ 28 days after primary series completed. Same dose as primary series

* Pfizer-BioNTech Doses (Use Age Appropriate Vials)
  - >12 years old: 0.3mL
  - 5-11 years old: 0.2mL
  - ≥ 5 months after primary series completed

**Moderna Vaccine**
- >18 years old: 0.5 mL x 2 doses 4-8 weeks apart

**Moderate to severely Immunocompromised**
- 2nd Additional Dose
  - Moderna or Pfizer >18 year old
  - ≥ 28 days after primary JJ vaccine.
  - Moderna 0.5mL or Pfizer 0.3mL

*Moderna Dose 0.25mL
  - ≥ 5 months after primary series completed
  - ≥ 18 years of age

**Janssen (J&J) Vaccine**
- >18 years: 0.5 mL single dose

*Janssen (JJ) Dose 0.5mL
  - ≥ 2 months after primary series completed
  - ≥ 18 years of age

**mRNA vaccines are preferred for primary and booster doses**

---

Everyone ages 50 years and older who received any COVID-19 booster dose—as well as everyone ages 12 years and older who are moderately or severely immunocompromised—SHOULD receive a second booster 4 months after the most recent dose using an mRNA COVID-19 vaccine.

Individuals 18-49 who received JJ for primary and booster MAY receive a second booster.

*Providers may provide heterologous (”mix and match”) booster doses to eligible individuals following completion of primary vaccination*

Those individuals who are moderately or severely immunocompromised should receive a booster 3 months after completion of the primary series and individuals 12 and older should receive a second booster 4 months after the first booster.

- Individuals 5-11 may receive a total of four COVID-19 vaccine doses
- Individuals who are 12 and older who received mRNA may receive a total of five COVID-19 vaccine doses
- Individuals who received JJ may receive a total of four vaccine doses

For more information: [Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/clinical-considerations.html)